Rapid Access to Contrast-Enhanced spectral mammogRaphy in women recalled from breast cancer screening: the RACER trial study design
DiscussionBased on previously published retrospective studies, we expect to demonstrate in this prospective multicenter randomized controlled trial, that using CESM as a primary work-up tool in women recalled from breast cancer screening is a more accurate, cost-effective, and patient-friendly strategy.Trial registration Netherlands Trial Register,NL6413/NTR6589. Registered on 6 July, 2017.
Source: Trials - Category: Research Source Type: clinical trials
More News: Anxiety | Breast Cancer | Cancer | Cancer & Oncology | Health Management | Mammography | Netherlands Health | Research | Study | Women